La Jolla Pharmaceutical Company
LJPC
LJPC was delisted on the 19th of August, 2022.
93 hedge funds and large institutions have $808M invested in La Jolla Pharmaceutical Company in 2017 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 37 increasing their positions, 27 reducing their positions, and 18 closing their positions.
37% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 27
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
2% less capital invested
Capital invested by funds: $828M → $808M (-$20.3M)
6% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 18
2% less funds holding
Funds holding: 95 → 93 (-2)
43% less call options, than puts
Call options by funds: $6.35M | Put options by funds: $11.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$40.2M |
| 2 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$17.2M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$8.26M |
| 4 |
GTC
Ghost Tree Capital
New York
|
+$6.54M |
| 5 |
AC
Ascend Capital
Orinda,
California
|
+$6.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$25.2M |
| 2 |
Allianz Asset Management
Munich,
Germany
|
-$7.72M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$6.7M |
| 4 |
ORI
Oak Ridge Investments
Chicago,
Illinois
|
-$4.81M |
| 5 |
D.E. Shaw & Co
New York
|
-$4.46M |
LJPC Hedge Fund Activity: Q4 2017 in Review
93 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q4 2017, worth a combined $808M — down 2.5% from $828M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of LJPC and 17 opened new positions — a net loss of 1 holder — while 27 trimmed existing stakes and 37 added.
The largest buyer was Perceptive Advisors, adding an estimated $40.2M. The largest seller was Redmile Group, exiting entirely with an estimated $25.2M sold.
- 93 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q4 2017, down from 95 in Q3 2017.
- Funds reported $808M of La Jolla Pharmaceutical Company stock for Q4 2017, down 2.5% quarter-over-quarter.
- 17 funds opened new La Jolla Pharmaceutical Company positions in Q4 2017 and 18 closed out, a net change of -1 holder.
- The largest La Jolla Pharmaceutical Company buyer in Q4 2017 was Perceptive Advisors, an estimated $40.2M added.
- The largest La Jolla Pharmaceutical Company seller in Q4 2017 was Redmile Group, an estimated $25.2M sold.
Based on aggregated 13F filings for Q4 2017.